159 related articles for article (PubMed ID: 29269578)
1. Exhaled breath to screen for malignant pleural mesothelioma: a validation study.
Lamote K; Vynck M; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Eur Respir J; 2017 Dec; 50(6):. PubMed ID: 29269578
[TBL] [Abstract][Full Text] [Related]
2. Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
Lamote K; Vynck M; Van Cleemput J; Thas O; Nackaerts K; van Meerbeeck JP
J Breath Res; 2016 Sep; 10(4):046001. PubMed ID: 27669062
[TBL] [Abstract][Full Text] [Related]
3. Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study.
Lamote K; Brinkman P; Vandermeersch L; Vynck M; Sterk PJ; Van Langenhove H; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Oncotarget; 2017 Oct; 8(53):91593-91602. PubMed ID: 29207669
[TBL] [Abstract][Full Text] [Related]
4. An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
Dragonieri S; van der Schee MP; Massaro T; Schiavulli N; Brinkman P; Pinca A; Carratú P; Spanevello A; Resta O; Musti M; Sterk PJ
Lung Cancer; 2012 Mar; 75(3):326-31. PubMed ID: 21924516
[TBL] [Abstract][Full Text] [Related]
5. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
[TBL] [Abstract][Full Text] [Related]
6. Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
Töreyin ZN; Ghosh M; Göksel Ö; Göksel T; Godderis L
Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32050546
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
8. Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline results.
Zwijsen K; Schillebeeckx E; Janssens E; Cleemput JV; Richart T; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
J Breath Res; 2023 Sep; 17(4):. PubMed ID: 37683624
[TBL] [Abstract][Full Text] [Related]
9. Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.
Di Gilio A; Catino A; Lombardi A; Palmisani J; Facchini L; Mongelli T; Varesano N; Bellotti R; Galetta D; de Gennaro G; Tangaro S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429446
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
11. Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population.
Gopar-Nieto R; Aguilar-Madrid G; Sotelo-Martínez L; Juárez-Pérez CA; Kelly-García J; Argote-Greene L; Ochoa-Vázquez MD; García-Bazán EM; Ramírez-Pérez J; Haro-García L; Jiménez-Ramírez C; Cabello-López A
Arch Med Res; 2015 Feb; 46(2):107-11. PubMed ID: 25707292
[TBL] [Abstract][Full Text] [Related]
12. Confounding effect of benign pulmonary diseases in selecting volatile organic compounds as markers of lung cancer.
Wang M; Sheng J; Wu Q; Zou Y; Hu Y; Ying K; Wan H; Wang P
J Breath Res; 2018 Sep; 12(4):046013. PubMed ID: 30102249
[TBL] [Abstract][Full Text] [Related]
13. A breath test for malignant mesothelioma using an electronic nose.
Chapman EA; Thomas PS; Stone E; Lewis C; Yates DH
Eur Respir J; 2012 Aug; 40(2):448-54. PubMed ID: 22183490
[TBL] [Abstract][Full Text] [Related]
14. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort.
Allione A; Viberti C; Cotellessa I; Catalano C; Casalone E; Cugliari G; Russo A; Guarrera S; Mirabelli D; Sacerdote C; Gentile M; Eichelmann F; Schulze MB; Harlid S; Eriksen AK; Tjønneland A; Andersson M; Dollé MET; Van Puyvelde H; Weiderpass E; Rodriguez-Barranco M; Agudo A; Heath AK; Chirlaque MD; Truong T; Dragic D; Severi G; Sieri S; Sandanger TM; Ardanaz E; Vineis P; Matullo G
Int J Cancer; 2023 Feb; 152(4):725-737. PubMed ID: 36305648
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
16. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
[TBL] [Abstract][Full Text] [Related]
17. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
18. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.
Fujii M; Fujimoto N; Hiraki A; Gemba K; Aoe K; Umemura S; Katayama H; Takigawa N; Kiura K; Tanimoto M; Kishimoto T
Cancer Sci; 2012 Mar; 103(3):510-4. PubMed ID: 22146010
[TBL] [Abstract][Full Text] [Related]
19. External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma.
Janssens E; Schillebeeckx E; Zwijsen K; Raskin J; Van Cleemput J; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804954
[TBL] [Abstract][Full Text] [Related]
20. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.
Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K
Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]